U.S. flag

An official website of the United States government

NM_000155.4(GALT):c.329G>A (p.Gly110Glu) AND not provided

Germline classification:
Conflicting interpretations of pathogenicity (2 submissions)
Last evaluated:
Nov 8, 2016
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000439035.3

Allele description [Variation Report for NM_000155.4(GALT):c.329G>A (p.Gly110Glu)]

NM_000155.4(GALT):c.329G>A (p.Gly110Glu)

Gene:
GALT:galactose-1-phosphate uridylyltransferase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
9p13.3
Genomic location:
Preferred name:
NM_000155.4(GALT):c.329G>A (p.Gly110Glu)
HGVS:
  • NC_000009.12:g.34647657G>A
  • NG_009029.2:g.6069G>A
  • NG_028966.1:g.473G>A
  • NM_000155.4:c.329G>AMANE SELECT
  • NM_001258332.2:c.51-175G>A
  • NP_000146.2:p.Gly110Glu
  • NC_000009.11:g.34647654G>A
  • NM_000155.2:c.329G>A
Protein change:
G110E
Links:
dbSNP: rs1057523885
NCBI 1000 Genomes Browser:
rs1057523885
Molecular consequence:
  • NM_001258332.2:c.51-175G>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000155.4:c.329G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000533677GeneDx
criteria provided, single submitter

(GeneDx Variant Classification (06012015))
Likely pathogenic
(Nov 8, 2016)
germlineclinical testing

Citation Link,

SCV000695689Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Aug 2, 2016)
germlineclinical testing

LabCorp Variant Classification Summary - May 2015.docx

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From GeneDx, SCV000533677.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The G110E missense variant in the GALT gene has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The G110E variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The G110E variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved in mammals, and the majority of in silico analysis models predict that this variant is probably damaging to the protein structure/function. Furthermore, missense variants in nearby residues (S112R, D113N, H114L) have been reported in the Human Gene Mutation Database in association with classic galactosemia (Stenson et al., 2014), supporting the functional importance of this region of the protein. In summary, we interpret the G110E variant as likely pathogenic; however, the possibility that it is benign cannot be excluded.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000695689.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Variant summary: The GALT c.329G>A (p.Gly110Glu) variant involves the alteration of a conserved nucleotide. 2/4 in silico tools predict a benign outcome (SNPs&GO not captured due to low reliability index). The variant is located in the last nucleotide position in exon 4. 5/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant is absent in 121370 control chromosomes. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories; nor evaluated for functional impact by in vivo/vitro studies. Because of the absence of clinical information and the lack of functional studies, the variant was classified as a variant of uncertain significance (VUS) until additional information becomes available.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 4, 2024